Aetion raised an additional $110 million in Series C funding, making its total funding $212 million. The real world evidence (RWE) company also noted a 100% customer renewal rate last year. RWE is becoming increasingly used in submissions to regulatory bodies, making Aetion attractive for both investors and pharma. Aetion recently partnered with the Institute for Clinical and Economic Review (ICER) by offering RWE for ICER’s drug assessments.
According to Aetion CEO Carolyn Magill, “We are focused on supporting our customers, building our business, building global standards for transforming data into evidence and doing this on such a scale that biopharma manufacturers, payers, providers, data providers and regulators can all look to use RWE more routinely in how they make these high-stakes decisions.” Read more here.
(Source: Zachary Brennan, Endpoints News, 5/11/21)